BioCardia (BCDA) Expected to Announce Quarterly Earnings on Wednesday

BioCardia (NASDAQ:BCDA) is expected to post its Q3 2025 results before the market opens on Wednesday, November 12th. Analysts expect BioCardia to post earnings of ($0.25) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Wednesday, November 12, 2025 at 4:30 PM ET.

BioCardia (NASDAQ:BCDA) last issued its earnings results on Monday, August 11th. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.10. On average, analysts expect BioCardia to post $-4 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

BioCardia Stock Up 1.6%

NASDAQ BCDA opened at $1.30 on Monday. The firm has a market cap of $13.80 million, a P/E ratio of -0.70 and a beta of 0.78. The company’s 50 day moving average is $1.54 and its 200-day moving average is $1.96. BioCardia has a 12-month low of $1.00 and a 12-month high of $3.20.

Insider Buying and Selling

In other BioCardia news, Director Simon H. Stertzer bought 398,400 shares of the firm’s stock in a transaction on Friday, September 19th. The shares were acquired at an average cost of $1.25 per share, for a total transaction of $498,000.00. Following the purchase, the director directly owned 591,054 shares of the company’s stock, valued at $738,817.50. The trade was a 206.80% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Peter Altman purchased 48,000 shares of the stock in a transaction on Friday, September 19th. The stock was acquired at an average cost of $1.25 per share, for a total transaction of $60,000.00. Following the acquisition, the chief executive officer owned 216,762 shares in the company, valued at approximately $270,952.50. This represents a 28.44% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired a total of 735,600 shares of company stock worth $920,164 over the last ninety days. 20.00% of the stock is owned by corporate insiders.

Institutional Trading of BioCardia

A hedge fund recently bought a new stake in BioCardia stock. Cetera Investment Advisers bought a new position in BioCardia, Inc. (NASDAQ:BCDA) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 20,275 shares of the company’s stock, valued at approximately $40,000. Cetera Investment Advisers owned approximately 0.37% of BioCardia as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 20.57% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioCardia in a report on Wednesday, October 8th. Wall Street Zen raised BioCardia to a “sell” rating in a report on Saturday, November 1st. HC Wainwright reiterated a “buy” rating and set a $25.00 price target on shares of BioCardia in a research report on Monday, September 22nd. Finally, Zacks Research raised shares of BioCardia to a “hold” rating in a report on Tuesday, September 23rd. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, BioCardia presently has an average rating of “Moderate Buy” and a consensus target price of $25.00.

About BioCardia

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.